Nystatin is commonly prescribed as prophylaxis in children beyond the neonatal age
Authors:
- The PASOAP GroupTGThe PASOAP Group
- Laura Ferreras-AntolinLFLaura Ferreras-Antolin
- 29 December 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in Medical Mycology
- Vol. 61 (1)
Abstract
The indications for nystatin as prophylaxis or treatment are limited. In the PASOAP (Pediatric Antifungal Stewardship Optimizing Antifungal Prescription) study, high use of nystatin in hospitalized children beyond the neonatal age was observed. In this report, we present the data on nystatin use in infants and children ≥ 3 months who participated in the PASOAP study. Nystatin was prescribed mainly for prophylaxis. Congenital heart disease, cystic fibrosis, and chronic renal disease were the most commonly reported conditions in children receiving prophylactic nystatin. There is sparse evidence supporting the use of nystatin prophylaxis beyond neonates; trials in specific pediatric patient groups are required.Keywords
Funding Information
- MRC Center for Medical Mycology (MR/N006364/2)
This publication has 17 references indexed in Scilit:
- Role of oral nystatin prophylaxis in cardiac surgery with prolongedextracorporeal circulationMycoses, 2017
- Progress in Definition, Prevention and Treatment of Fungal Infections in Cystic FibrosisMycopathologia, 2017
- Fungal infections in children in the early postoperative period after cardiac surgery for congenital heart disease: a single-centre experienceInteractive CardioVascular and Thoracic Surgery, 2016
- Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2015
- Long-Term Peritoneal Dialysis Experience: Quality Control Supports the use of Fluconazole to Prevent Fungal PeritonitisThe International Journal of Artificial Organs, 2013
- ESCMID guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp.Clinical Microbiology and Infection, 2012
- Oral nystatin prophylaxis in surgical/trauma ICU patients: a randomised clinical trialCritical Care, 2012
- Invasive fungal disease in PICU: epidemiology and risk factorsAnnals of Intensive Care, 2012
- Candida colonization and candidemia in a pediatric intensive care unitPediatric Critical Care Medicine, 2008
- The use of topical nonabsorbable gastrointestinal antifungal prophylaxis to prevent fungal infections in critically ill immunocompetent patients: A meta-analysisCritical Care Medicine, 2005